Roche nabs priority review for Eylea competitor; Italy's Angelini eyes CNS, rare disease startups with $35M Lumira fund
The teams at Roche and Genentech are off and running at the FDA, with regulators accepting a quick pitch for what would be the first bispecific antibody designed for the eye.
Roche announced late Wednesday that its application for faricimab has been accepted under priority review to treat wet AMD and diabetic macular edema. In addition, the submission for diabetic retinopathy was also accepted, the company said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.